Results 121 to 130 of about 676 (157)

A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022). [PDF]

open access: yesCureus
Giliberto S   +7 more
europepmc   +1 more source

The translational potential of sleep and circadian rhythm disturbances as a biomarker of Alzheimer's disease [PDF]

open access: yes, 2018
Feldman, HH   +8 more
core   +1 more source

The borderland down under. [PDF]

open access: yesJ Clin Sleep Med
Altree TJ, Barateau L.
europepmc   +1 more source

An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy. [PDF]

open access: yesSleep Med X
Mann GS   +5 more
europepmc   +1 more source

Healthcare Burden and Productivity Loss Due to Narcolepsy in Sweden. [PDF]

open access: yesClocks Sleep
Giertz A   +5 more
europepmc   +1 more source

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials. [PDF]

open access: yesContemp Clin Trials Commun
Taranto-Montemurro L   +7 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Solriamfetol for the Management of Excessive Daytime Sleepiness

Journal of Pharmacy Practice, 2021
Objective: To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). Methods: PubMed (1966 to January 2021) was searched using the terms solriamfetol, JZP-110, ADX-N05 and Sunosi.
Megan C Cuomo   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy